Screener
Rigel Pharmaceuticals RIGL Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | As of / March 31, 2026 | As of / December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Commitments | ||
| Stockholders’ equity: | ||
| Common stock | 18 | 18 |
| Additional paid-in capital | 1,414,394 | 1,414,322 |
| Accumulated other comprehensive (loss) income | (128) | 181 |
| Accumulated deficit | (1,014,387) | (1,023,041) |
| Total stockholders’ equity | 399,897 | 391,480 |
| Total liabilities and stockholders’ equity | $504,608 | $513,594 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's total liabilities & equity?
- Rigel Pharmaceuticals (RIGL) reported total liabilities & equity of $504.61M in Q1 2026.
- How has Rigel Pharmaceuticals's total liabilities & equity changed year-over-year?
- Rigel Pharmaceuticals's total liabilities & equity increased by 186.8% year-over-year, from $175.97M to $504.61M.
- What is the long-term trend for Rigel Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's total liabilities & equity has grown at a 36.0% compound annual growth rate (CAGR), from $110.38M to $513.59M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Rigel Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude